However, it negatively regulated ACSL4 levels in a targeted manner, inhibiting HCC cell migration, invasion, and proliferation, while promoting CD8+ T cell activation, thereby alleviating the malignant progression and immune escape of HCC. The gene discussed is CD8A; the disease is hepatocellular carcinoma.